TNF-α modulates the migratory response of mesenchymal stem cells to TRAIL

Cellular and Molecular Life Sciences

Volumn 67, Issue 8, 2010, Pages 1307-1314

  Corallini, Federica ^a   Secchiero, Paola ^a   Beltrami, Antonio Paolo ^b   Cesselli, Daniela ^b   Puppato, Elisa ^b   Ferrari, Roberto ^c   Beltrami, Cario Alberto ^b   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Heart failure; Inflammation; Mesenchymal stem cells; OPG; TNF ; TRAIL

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; PROTEIN BLOOD LEVEL; ACUTE DISEASE; CASE CONTROL STUDY; CELL MOTION; COMPARATIVE STUDY; CYTOLOGY; FOLLOW UP; HEART INFARCTION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ACUTE DISEASE; CASE-CONTROL STUDIES; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950605368     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-009-0246-5     Document Type: Article

References (43)

1. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711 (Pubitemid 26052456)
2. Feldman AM, Combes A, Wagner D, Kadokami T, Kubota T, Li YY, McTiernan C (2000) The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35:537-544 (Pubitemid 30167009)
3. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, Liu PP (2004) Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110:3221-3228 (Pubitemid 39525069)
4. Akasaka Y, Morimoto N, Ishikawa Y, Fujita K, Ito K, Kimura-Matsumoto M, Ishiguro S, Morita H, Kobayashi Y, Ishii T (2006) Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol 19:588-598
5. Kim YS, Park HJ, Hong MH, Kang PM, Morgan JP, Jeong MH, Cho JG, Park JC, Ahn Y (2009) TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci 14:2845-2856
6. Sun J, Li SH, Liu SM, Wu J, Weisel RD, Zhuo YF, Yau TM, Li RK, Fazel SS (2009) Improvement in cardiac function after bone marrow cell therapy is associated with an increase in myocardial inflammation. Am J Physiol Heart Circ Physiol 296:H43-H50
7. Simonet WS, Lacey DL, Dunstan C, Kelly M, Chang MS, Luthy R, Nhuyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
8. Zauli G, Secchiero P (2006) The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Fact Rev 17:245-257 (Pubitemid 44038614)
9. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192-1194 (Pubitemid 34988634)
10. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024-1028 (Pubitemid 36337751)
11. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P (2004) Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44:1970-1976 (Pubitemid 39473280)
12. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180 (Pubitemid 38625393)
13. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Fr0land SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461-2468 (Pubitemid 40696134)
14. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM (2005) Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28:2176-2180 (Pubitemid 41242464)
15. Shin JY, Shin YG, Chun CH (2006) Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 29:1664-1666 (Pubitemid 44127600)
16. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G (2006) An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236-2244
17. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA (2007) Relation of osteoprotegerin to coronary calcium and aortic plaque. Am J Cardiol 99:513-518
18. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M (2007) Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 28:1894-1903
19. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K (2008) Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51:627-633 (Pubitemid 351193104)
20. Nybo M, Rasmussen L (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease. A systematic literature review. Eur J Endocrinol 159:603-608
21. Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One 4:e4442
22. Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, Hülsmann M, Berger R, Mörtl D, Huber K, Wojta J, Pacher R (2009) Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30:789-796
23. Satoh D, Inami N, Shimazu T, Kajiura T, Yamada K, Iwasaka T, Nomura S (2009) Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis doi: 10.1007/sl 1239-009-0364-369
24. Li SC, Wang L, Jiang H, Acevedo J, Chang AC, Loudon WG (2009) Stem cell engineering for treatment of heart diseases: potentials and challenges. Cell Biol Int 33:255-267
25. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G (2008) Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stroma cells. Stem Cells 26:2955-2963
26. The Joint European Society of Cardiology/American College of CardiologyCommittee (2000) Myocardial infarction redefined-a consensus document for the redefinition of myocardial infarction. Eur Heart J 21:1502-1513
27. The Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur Heart J 16:741-751
28. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, Forti G, Capitani S, Zauli G (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965-1974 (Pubitemid 39094803)
29. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135 (Pubitemid 36753853)
30. Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737-1745 (Pubitemid 47121852)
31. Zauli G, Melloni E, Capitani S, Secchiero P (2009) Role of fulllength osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841-851
32. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105:199-206 (Pubitemid 40053083)
33. Turan RG, Brehm M, Koestering M, Tobias Z, Bartsch T, Steiner S, Picard F, Ebner P, Schannwell CM, Strauer BE (2007) Factors influencing spontaneous mobilization of CD34+ and CD 133+ progenitor cells after myocardial infarction. Eur J Clin Invest 37:842-851 (Pubitemid 350029211)
34. Grundmann F, Scheid C, Braun D, Zobel C, Reuter H, Schwinger RH, Müller-Ehmsen J (2007) Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction. Clin Res Cardiol 96:621-627 (Pubitemid 47400818)
35. Ozaki Y, Nishimura M, Sekiya K, Suehiro F, Kanawa M, Nikawa H, Hamada T, Kato Y (2007) Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev 16:119-129 (Pubitemid 46362597)
36. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ (2007) Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res 27:53-64 (Pubitemid 46185062)
37. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P (2007) MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109:4055-4063
38. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J (2007) Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 73:77-83 (Pubitemid 44853931)
39. Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113:816-826
40. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY (2007) Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 30:97-104 (Pubitemid 46985774)
41. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732-740 (Pubitemid 36457637)
42. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413-3419 (Pubitemid 40628180)
43. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G (2006) Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 114:1522-1530